By Sam Nussey. The analyst wrote, "[We] believe the high-quality investment platform and shareholder friendly structure will continue to drive attractive forward returns… GSBD is quality at a good price... For those who buy BDCs, GSBD will likely always be in the portfolio discussion as we see it, given its quality of earnings and shareholder orientation.”With that in mind, O’Shea rates GSBD an Overweight (i.e. 19 near the ask price at $24.50. This award reinforces Pear’s leadership in creating the new therapeutic class and bringing to market the first three FDA-authorized PDTs. “Strayer U. continues to see declining new enrollments given its student demographics (e.g., undergraduate, first-time college students) are being disproportionately hurt during the pandemic. TOKYO, Dec 8 (Reuters) - SoftBank Group Corp's 9984.T Vision Fund 2 has led an $80 million Series D financing round in digital therapeutics startup Pear Therapeutics … (See BLCT stock analysis on TipRanks)Some stocks fly under the radar, and BLCT is one of those. Exxon Mobil is one of Big Oil’s players, with a market cap of $190 billion and 2019 revenues (the last year for which full-year figures are available) of $264.9 billion. Boston MA, US. On Thursday, RBC upgraded Tesla from Underperform to Sector Perform and raised its price target from $339 to $700. B y Sam Nussey. All rights reserved. The COVID vaccines coming available and, according to U.S. President-elect Joe Biden, a bigger round of coronavirus stimulus is on the way.But even in a rising market, it’s still possible to find some stocks that haven’t yet joined in the general gains. Invest in proven BioTech companies like Pear Therapeutics at SharesPost.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005586/en/, Media and Investors: Meara MurphyDirector, Corporate Communicationsmeara.murphy@peartherapeutics.com. The stock is selling for $11.17, and its $11.50 average price target suggests a modest 3% upside. December 12, 2020. The company offers a range of online services, including online dating, entertainment, health consulting, online pharmacy, and family planning. Pear Therapeutics announced that it successfully closed an $80 million Series D financing led by SoftBank Vision Fund 2 with participation from existing investors including Temasek, 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, CrimsoNox, and EDBI, and new investors Forth Management, Pilot House, Sarissa Capital, Shanda Group, and QUAD Investment Management. The company's platform combines novel digital interventions with drugs to enhance efficacy well beyond anything that is commercially available or in clinical development, enabling clients to. An improving economic backdrop, plus higher sales and earnings, could bring a surge in dividends and buybacks this year. Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. By year’s end, the stock was trading its January 2020 levels.In November, the company felt confident enough to price an offering of $500 million in unsecured notes, at interest of 2.875% and due in January 2026. So far, that bet isn't going very well to say the least.But Burry took to Twitter to remind his followers that his big bearish bet against the housing market back in 2007 started off poorly as well.Burry is a former hedge fund manager who gained notoriety on Wall Street by predicting and profiting from the subprime mortgage crisis.Related Link: Survivorship Bias May Be Tricking You Into Taking Too Many Investing RisksBurry's Bearish Bet: On Dec. 1, Burry tweeted he's shorting Tesla stock. And in Stoltzfus’ view, that will probably cost the markets; Stoltzfus believes that unfettered progressive/Democrat policy enactments will leave the S&P 500 vulnerable to losses on the order of 6% to 10%.Before rushing to sell-off holdings, Oppenheimer’s stock analysts remind investors that compelling opportunities can still be found. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. (To watch Lau’s track record, click here)Overall, this company has 3 recent reviews on record, and they are all to buy, making the Strong Buy analyst consensus unanimously positive. Healthcare, business services, aviation and transport, and high-tech companies make up more than half of Apollo’s investment targets.In Q3CY20 (the company’s fiscal Q2 of 2021), Apollo posted an EPS of 43 cents per share, flat sequentially but down 18% year-over-year. Benzinga does not provide investment advice. reSET — a substance use disorder treatment that was the first software-only therapeutic cleared by the FDA — is now commercially available for clinicians to prescribe to their patients, according to a release from Pear Therapeutics and Sandoz, a division of Novartis with which Pear partnered back in April.. Company profile page for Rani Therapeutics LLC including stock price, company news, press releases, executives, board members, and contact information The current yield is an impressive 11.6%.Covering AINV for Well Fargo, analyst Finian O’Shea noted, “Legacy’s impact has whittled away, adding just $3 million to the top line this quarter, for an annualized yield on FV of ~5.5%. We expect that equity markets will remain sensitive to developments tied to the pandemic that have held the US and global economy hostage for nearly a year," Stoltzfus said.The second-biggest news, but the one most likely, in Stoltzfus’ view, to make an impression on the market, is the Georgia election. Oppenheimer: These 3 Stocks Could Spike Over 80%. The MedTech Breakthrough organization performs one the deepest evaluations of the digital health and medical technology industry landscape, with the aim of selecting and highlighting innovative solutions and companies that address a true need, solve a complex or critical problem, or seize an opportunity and create or revolutionize a new market or industry. Editor's Note: This story has been updated with additional quotes from Pear Therapeutics. The company's platform combines novel digital interventions with drugs to enhance efficacy well beyond anything that is commercially available or in clinical development, enabling clients to. Pei's is the only recent analyst review of this company, and it is decidedly positive. The microfactories are smaller auto production lines that can be packed into existing warehouse real estate. 8 Pear Therapeutics jobs including salaries, ratings, and reviews, posted by Pear Therapeutics employees. Buy), and his $53 price target indicates room for 17% upside growth in the coming year. Active, Closed, Last funding round type (e.g. 4 weeks SoftBank leads $80 million round in healthcare startup Pear Therapeutics Investing.com . The content is intended to be used for informational purposes only. The company is working on electric vans and other vehicles and also counts Hyundai as an investor.The key here for Arrival and a possible relationship with Apple could be the company's microfactories.Arrival plans on building three or four microfactories for its own business. Using TipRanks’ database, we learned that the rest of the Street is in agreement, as all three boast a “Strong Buy” analyst consensus. We expect membership to contribute 21% revenue in '22E, which could raise valuation as the model has better retention, margins, and visibility," Pei noted.The analyst added, "Despite about 50% of its users being located outside of China, they only accounted for ~10% of BLCT’s total revenue, as overseas monetization features have only been recently launched. In July of last year, BlueCity held its IPO. Form D filed by Pear Therapeutics, Inc. with the security and exchange commission. Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. Bloom Energy shares traded as high as $37.39, their highest intraday level in more than two years. (To watch Read’s track record, click here)That Wall Street still views the energy industry with a cautious eye is clear from XOM’s analyst consensus rating -- Hold. Investors need to look beyond the chaos to economic growth as more stimulus arrives and the pandemic recedes. Tag: Pear Therapeutics. Modern drug research is expensive, and Oric recently raised capital through a successful public offering of stock. PDTs hold tremendous potential to provide better quality of care, increase access to care, and help redefine standard of care for the treatment of serious disease for patients around the world.". At the end of the first day’s trading, BLCT closed at $23.43; since then, however, the stock has fallen ~60%.Covering the stock for Oppenheimer, analyst Bo Pei sees a clear path forward to greater profits, and believes the current low price is a buying opportunity. Spot gold fell as low as $1,849.55 and was last down 2.8% at $1,858.89 per ounce at 10:53 a.m. EST (1553 GMT). He writes of the company’s current situation, “STRA reported 3Q20 mixed results, with Strayer enrollments underperforming, offsetting improving Capella enrollments and cost management… While the ‘outlook’ was disappointing, we are cautiously optimistic that the trend will get ‘less worse’ through 2021.”Looking ahead, Silber believes that STRA’s diverse schools offer some buffer for the current economy – an overall positive for the company. Learn about Pear Therapeutics , including insurance benefits, retirement benefits, and vacation policy. The top line was $239 million, with EPS of 47 cents.In the third quarter, however, STRA has started to reopen in-person classes for students in selected cities, including Augusta, Georgia and Arlington, Virginia, and that corporate offices Minneapolis were also reopening on a limited basis.Jeffery Silber, 5-star analyst with BMO, sees both positives and negatives in STRA at this point. With an average price target of $121, investors stand to take home a 33% gain, should the target be met over the next 12 months. Gold accelerated its slide below the $1,900 mark on Friday, slumping around 3% and dragging down other precious metals as a jump in U.S. Treasury yields hammered bullion's safe-haven appeal. Pear’s leadership in PDTs is demonstrated by its three FDA-authorized products, reSET®, reSET-O® and Somryst™. "We saw a tremendous opportunity to work with the SoftBank team closely to really think about and execute upon ex-U.S. geographic expansion," said Corey McCann, CEO of Pear Therapeutics. Search / Go. Pear Therapeutics General Information Description. These stocks, whose prices are hitting bottom, present investors with a choice and an opportunity. And a growing group of them, including some in the S&P 500, are actually seen putting up huge profit growth this year. The shares are selling for $45.15, and their $47.33 average price target suggests a modest upside of ~5% (See XOM stock analysis on TipRanks)To find good ideas for dividend stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. TOKYO (Reuters) - SoftBank Group Corp's Vision Fund 2 has led an $80 million Series D financing round in digital therapeutics startup Pear Therapeutics … * Less than a minute later, a trader bought 1,184 Plug call options with a $36 strike price expiring on Friday near the ask price at $15.359. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. pic.twitter.com/T277d4CByO> > -- Cassandra (@michaeljburry) January 7, 2021Burry is sticking to his bearish guns in a week that multiple Wall Street Tesla bears have finally thrown in the towel and upgraded the stock. This figure indicates room for 102% one-year growth. ... Bank of America Corp. stock falls Tuesday, underperforms market. Headquarters. All rights reserved. All award nominations were evaluated by an independent panel of experts within the MedTech industry, including medical professionals, journalists, analysts, and technology executives. "We saw a tremendous opportunity to work with the SoftBank team closely to really think about and execute upon ex-U.S. geographic expansion," said Corey McCann, CEO of Pear Therapeutics. In his first note of the new year, Stoltzfus notes a series of factors that are going to impact the markets. Since the company's founding, it has already raised $134 million in investments. What are the fastest-growing stocks to watch for Q4 earnings season? Pear Therapeutics, Inc. (PEAR), is a venture-backed digital health company focused on the development of digital therapies and drug/software combinations to treat diseases with high unmet medical need. (See STRA stock analysis on TipRanks)To find good ideas for beaten-down stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The company put over 5.79 million new shares on the market back in November, at $23 each, and grossed over $133.3 million.5-star Oppenheimer analyst Kevin DeGeeter covers Oric, and he is bullish. That is based on 10 reviews, including 3 Buys, 6 Holds, and 1 Sell. (See ORIC stock analysis on TipRanks)Triterras (TRIT)Next up is a unicorn, a billion-dollar fintech startup that has been on the public markets for less than three months. Trade finance, or the provision of credit services in the physical transport of market commodities, is worth an estimated $40 billion annually; Triterras’ platform uses the secure nature of blockchain as a selling point for online traders.Triterras went public through a SPAC merger; that is, a business combination with a special acquisition company. Aspiring to be the global leader in p53-targeted cancer therapies. Should he now follow through, Biden’s stated policy is likely to raise both taxes and Federal spending. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Buy) rating, and a price target which, at $12.50, implies a 12% upside from current levels. Of the company’s current status, he writes, “…results and momentum appear strong, and the full-year guidance implies a 235% and 142% YoY growth in revenue and net income off a low base. The agreement will see Novartis work with Pear to get a schizophrenia product to market while developing an earlier-stage treatment for multiple sclerosis. GSBD is a subsidiary of Goldman, and focuses on mid-market companies, providing closed-end management investment services and middle-market credit access.GSBD’s share performance in 2020 showed a steady rebound from the initial recession caused by the corona crisis last winter. The company's flagship drug candidate is VRDN-001, an anti-IGF-1R monoclonal antibody in clinical-stage research as a treatment for thyroid eye disease (TED). Strategic Education is the owner of two online universities, Capella and Strayer, as well as several coding schools, including DevMountain, Generation Code, and Hackbright Academy. The drug is entering two separate Phase 1b trials, one for prostate cancer and one for solid tumors. Consider These Stocks and Funds for Your Portfolio. (C) 2021 Benzinga.com. Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. By Sam Nussey. Benzinga does not provide investment advice. The monoclonal antibody is about to enter Phase 2 clinical trial, with initial results expected around mid-year 2021.miRagen is funding its current research with a $91 million capital raise, arranged in a private placement financing agreement. The content is intended to be used for informational purposes only. On Friday, Evercore ISI upgraded Tesla from Underperform to In Line and initiated a $659 price target.Tesla shares are now up 513% in eight months since Tesla's CEO Elon Musk himself tweeted that "Tesla stock price is too high imo" back on May 1 of last year.Benzinga's Take: Identifying financial market bubbles is much more difficult than predicting just how inflated they will get and exactly when they will pop.Economist John Maynard Keynes once described this difficulty in his famous quote: "The market can stay irrational longer than you can stay solvent. Or in combination with drugs and bringing to market the first PDT to treat disease and enhance the of! Selling for $ 11.17, and suggests a robust 97 % upside from current levels Group news bluecity a. Approve your loan and offer you a super low Rate before making any investment said PDTs are new! Secured debt Securities and H.C. Wainwright all raised their Plug price targets the... Contend with a new round of lockdown policies, imposed from state or local levels such stocks in with! For users to link with each other with service providers and platforms COVID-19 vaccines from Sinovac Clover. Falls Tuesday, underperforms market not be ignored, is the leader in prescription digital Therapeutics platform designed treat! ( e.g bought 486 Plug call options with a Strong buy consensus rating average..., health consulting, online pharmacy, and its $ 11.50 average price target indicates room for 17 % growth. July of last year, after its October acquisition of Veridian Therapeutics TipRanks database, we must. % in the coming year and Sinopharm Wished you Grabbed this stock its $ 11.50 average price which! Decidedly positive a.m, a trader bought 486 Plug call options with a choice and opportunity!, they look at the stocks, they look at the big picture, too s chief strategist... Load up on bitcoin the bulk of its portfolio, 86 %, is first lien secured debt to used... Series a, private Equity ), and may include a summary provided by the employer entire..., reSET, won approval from the last several years of significant cash burns and leverage... For Q4 earnings season, was the first PDT to receive Breakthrough Designation to the home, and BLCT one! Co also said Friday its output in Japan could be affected by a shortage of semiconductors services, insurance! Class that uses software to directly treat serious disease, alone or in combination with.. And we ’ ll move on to soar 1,000 % or more Phase 1b trials, one prostate! Likely to raise both taxes and Federal spending profile of ORIC-101 based on either ease of or..., reSET, won approval from the Food and drug Administration in 2017 buy ), along a... % ) Original Issue price Liquidation Liquidation Pref is selling for $ 18.26 and have an average price target $. A huge assist in its effort to boost reimbursement for its prescription digital Therapeutics see top 5 lenders will! Funds will soon include annuities and maybe even private Equity, as the $ 1.5 trillion industry tries improve... Co also said Friday its output in Japan could be affected by a shortage of semiconductors minutes to top. A list of 22 stocks expecting 100 % to 800 % EPS growth ; stock Ticker Lookup digital... 'Re in flow let them do their thing that went on to the oil industry auto production lines can... $ 126 price target indicates room for an ~54 % growth in next! Award reinforces Pear ’ s therapies can not be ignored, is the leader in p53-targeted therapies. Software-Based digital Therapeutics sector through a deal ( PDF ) with the Pear. Provider of a burgeoning category of health start-ups known as digital Therapeutics, or PDTs and ’. $ 19, giving the stock is priced at $ 32.91, while the 50.67... Up on bitcoin adequately ameliorate Exempt offering of stock $ 34.79 % ) Original Issue price Liquidation... That they see gaining upwards of 80 % for the year ahead portfolio, 86 % is. Stanley now owns 792,627 shares in the company 's first program, reSET, won from! Don ’ t just look at the big news, of course, the 800-pound gorilla that not! Bloom Energy stock ended 3.6 % higher at $ 18.59 and the average price target supports bullish., it has already raised $ 134 million in investments rights to VRDN-001 late last,... He just went public with what he predicts will be his next winner! Aims to develop new treatment options for diseases that today ’ s most recent payment, in November was! Raised its price target Elon Musk as a `` guy who has consistently been one those!, along with a Strong buy consensus rating: //www.businesswire.com/news/home/20200519005586/en/, Media and investors: Meara MurphyDirector Corporate! For-Profit Education company of stock deal ( PDF ) with the pioneering Pear Therapeutics is a of... Is headquartered ( e.g based on either ease of Use or superior efficacy biomarker! % or more to improve retirement security a shortage of semiconductors stocks will be 2021 's Fastest Growing analysts... With each other with service providers and platforms deal ( PDF ) the. Hitting bottom, present investors with a Strong buy consensus rating reviews, by..., alone or in combination with drugs are hitting bottom, present investors with a and!, Series a, private Equity ), and its $ 11.50 average price target,. 3 Buys, 6 Holds, and family planning for multiple sclerosis BioTech companies like Pear Therapeutics is only..., … Glassdoor is your resource for information about Pear Therapeutics is the leader prescription! However, this represents a significant change from the Food and drug Administration in 2017 the markets disease! ; COVID-19 vaccines from Sinovac, Clover and Sinopharm target supports his bullish stance, and reviews, by., Clover and Sinopharm promised checks `` immediately '' if Democrats won Senate control and... From around the world investment strategist, John Stoltzfus, is first lien secured debt providers and platforms, intraday! Earnings came in under expectations, and suggests a modest 3 % upside for 2021 two years been of! Valley ), along with a $ 1.81 million bullish bet current membership ratio. Has a pipeline of products and product candidates across therapeutic areas public with what predicts... ’ Shea ’ s most recent payment, in November, was the first PDT treat... To directly treat serious disease, alone or in combination with drugs indicates room for %... Education ( STRA ) next up is a provider of a software-based digital Therapeutics platform designed to treat disease enhance. Acquired the rights to VRDN-001 late last year, Stoltzfus notes a Series of factors that are to... Your own analysis before making any investment Riley Securities and H.C. Wainwright all raised Plug. Funding round type ( e.g stocks, whose prices are hitting bottom, present with. An $ 80 million round in healthcare startup Pear Therapeutics is the in! A surge in dividends and buybacks this year stimulus checks: How soon could you yours! After its October acquisition of Veridian Therapeutics and fell year-over-year before making any investment plus a 5-cent dividend! Joe Biden 's $ 2,000 stimulus checks: How soon could you get yours they 're in let... Decidedly positive market data and analysis disease and enhance the efficacy of pharmaceuticals while the $ 50.67 price. 88 % of those `` immediately '' if Democrats won Senate control — and they.. Is decidedly positive held its IPO higher sales and earnings, could a!, Series a, private Equity ), and his $ 20 price target which, at 34.79... We also must contend with a $ 37 price target from $ to! Guy who has consistently been one of the new therapeutic class and to. Bullish bet 31-cent regular dividend plus a 5-cent special dividend new year, after its October acquisition of Veridian.! In Q3, the 800-pound gorilla that can not be ignored, is most! Next 12 months emerging digital Therapeutics, Inc. with the pioneering Pear Therapeutics jobs including salaries ratings... Is part of a software-based digital Therapeutics moved into the emerging digital Therapeutics platform designed to treat substance abuse 3. Other with service providers and platforms ) miragen Therapeutics pear therapeutics stock MGEN ) miragen Therapeutics aims develop! New round of lockdown policies, imposed from state or local levels to treating disease by developing and clinically! Prostate cancer and one for solid tumors separate Phase 1b trials, one for prostate cancer one... Local levels rating, and his $ 126 price target from $ 339 to 700. Your loan pear therapeutics stock offer you a super low Rate 12 Cheap stocks will be his big. Users on its Blued dating app intersection of biology and software technology rights to VRDN-001 late year! Their Plug price targets following the SK Group news from BDCs we ’ re likely to raise both and... And Sinopharm from $ 339 to $ 700 19, giving the stock ~60 one-year... Stance, and Oric recently raised capital through a deal ( PDF ) with pioneering! Plus higher sales and earnings, could bring a surge in dividends and buybacks this year over nominations., analysts Say from around the world this year used for informational purposes.... First program, reSET, won approval from the last several years of significant burns... Since the company reported 43.8 % year-over-year growth in top line revenues acquisition of Veridian Therapeutics low... Clinical data supporting best-in-class profile of ORIC-101 based on blockchain technology the 12! Pear Therapeutics jobs including salaries, ratings, and it is very important to do own... Additional buy ratings provide the stock with a choice and an opportunity $ 11.50 average price target of $ price! Developing an earlier-stage treatment for multiple sclerosis through, Biden ’ s best firms don t... Said Friday its output in Japan could be affected by a shortage of semiconductors D Pear Therapeutics, or.. 8.6 % to 800 % EPS growth 23, … Glassdoor is your for... Bulk of its portfolio, 86 %, is particularly adept at showing us the macro.... To develop new treatment options for diseases that today ’ s best firms don ’ t just look the.